Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan I Silverberg

Showing results (401-410 of 670) with videos related to

Pageof 67
Sort By:
Journal of the American Academy of Dermatology|February 10, 2024
Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a studyJonathan I Silverberg, Robert S Kirsner, David J Margolis, et al.
Journal of Drugs in Dermatology : JDD|October 6, 2023
Selection of Nemolizumab Clinical Dosage for Atopic DermatitisNathalie Wagner, Luca Loprete, Vincent Duval, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 14, 2022
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7Jonathan I Silverberg, Eric L Simpson, Jacob Pontoppidan Thyssen, et al.
Journal of Drugs in Dermatology : JDD|October 7, 2020
Clinical Relevance of Skin Pain in Atopic DermatitisSonja Ständer, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 8, 2022
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tabletsRichard B Warren, Bruce Strober, Jonathan I Silverberg, et al.
JAMA Dermatology|June 4, 2020
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialJonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, et al.
Health and Quality of Life Outcomes|October 24, 2021
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitisJonathan I Silverberg, Amy DeLozier, Luna Sun, et al.
The Journal of Investigative Dermatology|December 21, 2018
Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 21, 2018
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional studyJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 10, 2018
Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Pageof 67

Showing results (401-410 of 670) with videos related to

Sort By:
Pageof 67
Journal of the American Academy of Dermatology|February 10, 2024
Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a studyJonathan I Silverberg, Robert S Kirsner, David J Margolis, et al.
Journal of Drugs in Dermatology : JDD|October 6, 2023
Selection of Nemolizumab Clinical Dosage for Atopic DermatitisNathalie Wagner, Luca Loprete, Vincent Duval, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 14, 2022
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7Jonathan I Silverberg, Eric L Simpson, Jacob Pontoppidan Thyssen, et al.
Journal of Drugs in Dermatology : JDD|October 7, 2020
Clinical Relevance of Skin Pain in Atopic DermatitisSonja Ständer, Eric L Simpson, Emma Guttman-Yassky, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 8, 2022
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tabletsRichard B Warren, Bruce Strober, Jonathan I Silverberg, et al.
JAMA Dermatology|June 4, 2020
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialJonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, et al.
Health and Quality of Life Outcomes|October 24, 2021
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitisJonathan I Silverberg, Amy DeLozier, Luna Sun, et al.
The Journal of Investigative Dermatology|December 21, 2018
Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 21, 2018
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional studyJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 10, 2018
Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Pageof 67